drugset / Trial / NCT00207155
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to predict response to Erbitux as a single agent in patients with metastatic colon cancer
Timeline
- Start
- 2003-12
- Primary completion
- 2006-02
- Completion
- 2006-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | 250 mg/m2 | Intravenous |
| Subject | Cetuximab | Monoclonal antibody | 400 mg/m2 | Intravenous |